BCT-101
Biocentra-101
A selective tyrosine kinase inhibitor targeting HER2-positive metastatic breast cancer with improved CNS penetration.
BCT-102
Biocentra-102
A novel PCSK9 inhibitor that significantly reduces LDL cholesterol in patients with familial hypercholesterolemia.
BCT-103
Biocentra-103
An NMDA receptor antagonist designed to slow cognitive decline in patients with moderate-to-severe Alzheimer's disease.
BCT-104
Biocentra-104
A next-generation anti-PD-1 immune checkpoint inhibitor with enhanced efficacy against solid tumors.
BCT-105
Biocentra-105
An oral factor XIa anticoagulant designed to prevent thrombotic events with reduced bleeding risk compared to standard therapies.
BCT-106
Biocentra-106
A precision therapy targeting LRRK2 mutations in Parkinson's disease, designed to slow or halt disease progression.
BCT-107
Biocentra-107
A groundbreaking AAV9-based gene therapy delivering functional SMN1 gene copies for spinal muscular atrophy patients.
BCT-108
Biocentra-108
An mRNA-based therapy designed to restore functional CFTR protein expression in cystic fibrosis patients regardless of mutation class.